Eskata Now Available to Treat Raised Seborrheic Keratoses

Seborrheic keratosis (a benign skin lesion resulting from excessive growth of the top layer of skin
Seborrheic keratosis (a benign skin lesion resulting from excessive growth of the top layer of skin
Eskata is a high-concentration hydrogen peroxide-based topical solution intended for in-office application.

Eskata (hydrogen peroxide), the first FDA-approved topical treatment for raised seborrheic keratoses, has been made available by Aclaris Therapeutics. This high-concentration stabilized hydrogen peroxide topical solution is designed for in-office application by a healthcare professional.

Eskata is a targeted treatment that is applied directly to the raised seborrheic keratoses. “Though not life threatening, raised [seborrheic keratoses] can make patients feel self-conscious, yet the majority of these lesions go untreated,” said Marina Peredo, MD, FAAD, an associate clinical professor of Dermatology at Mount Sinai Hospital in New York and founder of Skinfluence, a dermatology practice on the Upper East Side of Manhattan.  “Now, with the introduction of Eskata, my colleagues and I finally have a topical treatment option.” 

Treatment typically includes a single in-office session where Eskata is applied to the lesions 4 times, approximately 1 minute apart. If the treated lesion have not completely cleared approximately 3 weeks after treatment, another treatment may be administered following the same procedure. When treating lesions on the face, appropriate steps should be taken to avoid contact with the eyes.

The most common adverse reactions associated with treatment include erythema, stinging, edema, scaling, crusting, and pruritus

Related Articles

Eskata is available as a 40% (w/w) topical solution in 1.5mL and 2.2mL fill volume applicators in 1-, 3-, and 12-count cartons.  Healthcare providers are advised to wear nitrile or vinyl examination gloves during the activation of the Eskata applicator and during the administration of the solution to the lesions.


For more information call (833) 225-2747 or visit

This article originally appeared on MPR